BiotechTube
ProteinLogic

ProteinLogic

Cambridge, United Kingdom· Est.
proteinlogic.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $1.7M

Overview

Founded in 2004 and based in Cambridge, UK, ProteinLogic is a private diagnostics company pioneering a novel approach to disease detection and monitoring. Its core ImmiPrint® platform analyzes patterns of soluble Cluster of Differentiation (sCD) antigens using high-throughput immunoassays and machine learning to generate disease-specific diagnostic signatures. The company has clinically validated its first signature for Active Tuberculosis and holds an early-stage pipeline targeting infectious, autoimmune, and inflammatory diseases, positioning it in the growing field of precision diagnostics.

Infectious DiseaseAutoimmune DiseasesInflammatory Diseases

Technology Platform

ImmiPrint® platform uses high-throughput immunoassays to measure patterns of soluble Cluster of Differentiation (sCD) antigens in body fluids, which are analyzed by machine learning to generate disease-specific diagnostic signatures.

Funding History

2
Total raised:$1.7M
Seed$1.2M
Grant$500K

Opportunities

The validated TB test addresses a massive WHO-prioritized unmet need in global health, offering a clear near-term commercialization path.
The platform's ability to generate multi-analyte signatures for diverse diseases positions the company to capitalize on the growing markets for precision diagnostics, companion diagnostics, and autoimmune disease testing.

Risk Factors

Key risks include the platform validation risk beyond TB, heavy reliance on securing a major diagnostics partner for commercialization, and the regulatory and reimbursement challenges inherent to novel, algorithm-based diagnostic devices.
As a small, private company, it also faces funding and execution risks.

Competitive Landscape

ProteinLogic competes in the broad diagnostics market against large IVD companies and numerous startups using genomics, proteomics, and AI. Its unique focus on a defined set of sCD biomarkers differentiates it from broader 'omics' approaches. For TB, it competes with other non-sputum triage tests like Cepheid's Xpert MTB/RIF Ultra and various lateral flow assays.

More companies in Diagnostics & Precision Medicine →More companies in United Kingdom →